RWJ 50271

RWJ 50271化学性质

RWJ 50271性质、用途与生产工艺

生物活性 RWJ 50271 是一种选择性的，具有口服活性的 LFA-1/ICAM-1 相互作用抑制剂，IC50 值为 5.0 μM (HL60 cells)。RWJ 50271 抑制 LFA-1/ICAM-1 介导的细胞粘附。
靶点

IC50: 5.0 μM (LFA-1/ICAM-1, HL60 cells)
体外研究

RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 inhibits both human and murine NK activity (IC ₅₀ =5.0 μM) in an LFA-1/ICAM-1-dependent natural killer [NK] cytotoxicity assay.
RWJ 50271 does not inhibit Mac-1/ICAM-1, E-selectidsialyl Lewis X or VLA-4/VCAM-1-mediated cell adhesion up to 20 μM concentrations.
RWJ 50271 does not alter the LFA-1 expression levels on HL60 cells.
RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 does not exhibit any toxic activity up to 100 μM concentrations.

体内研究

RWJ 50271 (50 mg/kg; p.o.) is effective in animal model of inflammation.

Animal Model:	Mice, the delayed-type hypersensitivity [DTH] reaction model
Dosage:	50 mg/kg
Administration:	Oral administration
Result:	Significantly reduced foot pad swelling (>50%) 48 h after the challenge.

RWJ 50271上下游产品信息

上游原料

下游产品

RWJ 50271 试剂级价格

RWJ 50271生产厂家